The Cancer institute of New Jersey (CINJ) is a matrix style, basic, clinical and population research center under the auspices of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. The Director serves as Associate Dean for Oncology Programs and is responsible for integrating research at the medical school with the Robert Wood Johnson University Hospital, School of Public Health, and several schools and departments of Rutgers University. CINJ was awarded its first P30 Cancer Center Support Grant (P30 NCI 072720) on March 1, 1997. CINJ has a current membership of 155, whose peer reviewed, funded research projects, as defined by the CCSG guidelines, total more than $50 million in direct costs, nearly $15 million of which is from the NCI. The research base of CINJ is organized into eight programs: Breast Cancer Research; Cancer Pharmacology/Developmental Therapeutics; Carcinogenesis and Chemoprevention; Cytokines, Cytokine Signaling and Cancer; Molecular Mechanisms of Tumor Growth; Prostate; Population Science, and Transcriptional Regulation and Oncogenesis. This application requests support for the following: Administration; Data Safety and Monitoring; Developmental Funds; Planning and Evaluation; Program Leaders; Protocol Review and Monitoring System; Protocol Specific Research; and Senior Leadership. In addition, we are requesting funds for the following shared resources of CINJ: Analytical Cytometry/Image Analysis; Centralized Education and Training for Clinical Research Personnel; DNA Sequencing; Immunohistochemistry; Laboratory Support Services; Office of Human Resource Services; Research Pharmacy; Tissue Retrieval Service; Transcriptional Profiling; and Transgenic/Knock-out Mouse Service.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-11S2
Application #
7499924
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-03-01
Project End
2010-02-28
Budget Start
2007-09-24
Budget End
2008-02-29
Support Year
11
Fiscal Year
2007
Total Cost
$127,296
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3

Showing the most recent 10 out of 775 publications